Sentences with phrase «drug pembrolizumab»

Merck's anti-PD-1 drug pembrolizumab (MK - 3475) is currently being investigated in a large a phase I trial for patients with metastatic melanoma and lung cancer.

But the disease did recur in the other 2 patients with stage IV melanoma, though both responded to further treatment using the immunotherapy drug pembrolizumab.

On October 2, 2015, the FDA approved the immunotherapy drug pembrolizumab (Keytruda ®), made by Merck, as second - line treatment for patients with lung cancer, the leading cause of cancer - related death in the U.S. and the world.

At that point, they began treatment with the drug pembrolizumab, which inhibits the PD - 1 immune checkpoint.

The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to...

The immunotherapy drug pembrolizumab — already FDA - approved for other forms of cancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Center.

In a phase 1b clinical trial with 21 patients, researchers tested the safety and efficacy of combining the immunotherapy drug pembrolizumab with an oncolytic virus called T - VEC.

Not exact matches

On May 23, the Food and Drug Administration approved pembrolizumab for cancer patients with mismatch repair mutations for whom other drugs have failed.

The drug, Keytruda (pembrolizumab), was tested on more than 600 patients who had melanoma that had spread throughout their bodies.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

Since approving ipilimumab five years ago, the Food and Drug Administration has OK'd two similar drugs — pembrolizumab and nivolumab — for melanoma and certain lung cancers.

Drugs like pembrolizumab boost the response in tumors where immune cells are present but don't work in tumors where there is no immune response to boost.

«Although only a small subset of women responded to the drug, within that subset pembrolizumab worked extremely well and responses were durable,» Adams adds.

«Immunotherapy drug effective for metastatic triple negative breast cancer: Pembrolizumab shown to shrink tumors — regardless of whether patient had prior treatment.»

In 2017, the U.S. Food and Drug Administration (FDA) approved the cancer drug Keytruda (pembrolizumab) for a range of solid tumors that are either microsatellite instability - high (MSI - H) or mismatch repair deficient (dMDrug Administration (FDA) approved the cancer drug Keytruda (pembrolizumab) for a range of solid tumors that are either microsatellite instability - high (MSI - H) or mismatch repair deficient (dMdrug Keytruda (pembrolizumab) for a range of solid tumors that are either microsatellite instability - high (MSI - H) or mismatch repair deficient (dMMR).

PD -1-blocking agents such as nivolumab, pembrolizumab and atezolizumab are part of a class of drugs known as checkpoint inhibitors, and many cancer researchers are now trying to figure out how to enhance their activity by combining them with other types of drugs.

One patient was treated with the immunotherapy pembrolizumab and now more than a year after starting treatment remains on the drug with 77 percent tumor reduction and no new metastases.

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.

In fact, the Food and Drug Administration's approval of pembrolizumab in May 2017 for adult and pediatric patients with solid tumors and high microsatellite instability, was the first time it had approved a cancer treatment based on a genetic feature rather than the cancer's location of origin.

Up popped a trial at Hopkins, where doctors were testing a drug called pembrolizumab.

The FDA also approved another immunotherapy drug, Merck's pembrolizumab, known commercially as Keytruda, for patients with tumors harboring this defect regardless of cancer type.

The Food and Drug Administration has cleared four checkpoint inhibitors for adults: Yervoy, also known as ipilimumab; Keytruda, or pembrolizumab; Opdivo, or nivolumab, and Tecentriq, or atezolizumab.

The immunotherapy drugs are ipilimumab (Yervoy ®), pembrolizumab (Keytruda ®), nivolumab (Opdivo ®), and talimogene laherparepvec (T - VEC, Imlygic ™).

If approved by the FDA in October for the treatment of refractory melanoma, pembrolizumab would be the first PD - 1 checkpoint inhibitor approved in its class, beating out BMS's nivolumab in the race to the finish line — or starting line, really, since both drugs will likely have multiple future uses.

«Although only a small subset of women responded to the drug, pembrolizumab worked extremely well in that subset and responses were durable,» Dr. Adams adds.

The study consists of two phases and involves two promising immunotherapy drugs: pembrolizumab and talimogene laherparepvec (T - VEC).

The drug, Keytruda or pembrolizumab, uses the body's own immune system to kill cancer tumors.

The drug he was given, pembrolizumab (brand name Keytruda), is part of a rapidly growing class of drugs called immunotherapy, which uses the body's immune system to fight the cancer.